HF
JNCE

HRT Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

HRT Financial’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,010
Closed -$60K – 3760
2022
Q2 		$60K Buy
+20,010
New +$97.3K ﹤0.01% 2497
2021
Q3 		– Sell
-22,255
Closed -$151K – 3926
2021
Q2 		$151K Sell
22,255
-19,711
-47% -$164K ﹤0.01% 2484
2021
Q1 		$430K Buy
+41,966
New +$460K ﹤0.01% 1893

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

HRT Financial's JNCE Position: Q3 2022 in Review

HRT Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 20,010 shares — an estimated $60K sold.

HRT Financial first reported a position in JNCE in Q1 2021 and held it in 3 quarters. The position peaked at $430K in Q1 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • HRT Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • HRT Financial sold 20,010 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $60K.
  • HRT Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • HRT Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $430K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.